Abstract:Ovarian cancer, a complex and aggressive malignancy, remains a significant challenge in clinical oncology due to its heterogeneous nature and limited therapeutic options. In this study, across Pakistani ovarian cancer patients, we conducted a comprehensive analysis of mutations within the BRCA1 and BRCA2 genes to elucidate their potential implications in ovarian cancer susceptibility and progression. Employing Next-Generation Sequencing (NGS), we conducted a comprehensive mutational analysis of BRCA1/2 genes. Kaplan Meier analysis was used to analyze the effect of pathogenic mutations on the survival outcomes of ovarian cancer patients. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and Immunohistochemistry (IHC) analyses were conducted to analyze the downstream effect of the pathogenic mutations. Targeted bisulfite sequencing (bisulfite-seq) analysis facilitated the investigation of epigenetic contributions to gene expression regulation. Enrichment analysis was conducted to uncover significant Gene Ontology (GO) terms and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways associated with BRCA1/2. Exploring DrugBank, we identified potential drugs capable of modulating BRCA1/2 expression regulation. NGS analysis identified three clinically significant pathogenic mutations within the BRCA1 gene and two within the BRCA2 gene, shedding light on their potential involvement in ovarian cancer susceptibility and progression. Kaplan Meier analysis unveiled poor overall survival (OS) associated with the identified pathogenic mutations, accentuating their prognostic value. Expression analysis using reverse transcriptionquantitative polymerase chain reaction (RT-qPCR) and IHC demonstrated a significant up-regulation of BRCA1 and BRCA2 genes in ovarian cancer samples harboring pathogenic mutations. Bisulfite-seq revealed a significant hypomethylation within promoter regions of mutated BRCA1 and BRCA2 genes in ovarian cancer samples, compared to non-mutated cases with pathogenic mutations, indicating the role of epigenetics in expression dysregulation as well. By uncovering clinically significant pathogenic mutations in BRCA1/2 genes and establishing their link with up-regulated gene expression, this study significantly advances our understanding of ovarian cancer's underlying causes in the Pakistani population.

BRCA mutations: Implications of genetic testing in ovarian cancer

BRCA mutations in the manifestation and treatment of ovarian cancer.

Breast cancer (BRCA) gene testing in ovarian cancer.

BRCA genetic testing and counseling in breast cancer: how do we meet our patients' needs?

BRCA-mutated breast cancer: the unmet need, challenges and therapeutic benefits of genetic testing

A universal genetic testing initiative for patients with high-grade, non-mucinous epithelial ovarian cancer and the implications for cancer treatment

The BRCA Gene in Epithelial Ovarian Cancer

A New Paradigm Of Genetic Testing For Hereditary Breast/Ovarian Cancers

Temporal Patterns and Adoption of Germline and Somatic BRCA Testing in Ovarian Cancer

Complexity of the Genetic Background of Oncogenesis in Ovarian Cancer—Genetic Instability and Clinical Implications

Retrospective analysis of non-BRCA gene pathogenicity variation in Chinese patients with ovarian cancer.

Breast cancer outcomes in women with ovarian cancer and a pathogenic germline BRCA mutation

Detection of clinically important BRCA gene mutations in ovarian cancer patients using next generation sequencing analysis

Detection of BRCA1/2 Mutation and Analysis of Clinicopathological Characteristics in 141 Cases of Ovarian Cancer

BRCA screening, treatment patterns and response among patients with ovarian cancer in the second line treatment setting: results from a real world survey

BRCA1/2 Mutation Testing in Patients with HER2-Negative Advanced Breast Cancer: Real-World Data from the United States, Europe, and Israel

How BRCA and homologous recombination deficiency change therapeutic strategies in ovarian cancer: a review of literature

BRCA Mutation Frequency and Clinical Features of Ovarian Cancer Patients: A Report from a Chinese Study Group

Differential Sensitivity of Germline and Somatic BRCA Variants to PARP Inhibitor in High-Grade Serous Ovarian Cancer

Real-world prevalence, treatment and survival of "high risk" early breast cancer, with mandatory testing of gBRCA1/2 mutation according to the OlympiA trial inclusion criteria: Data from a population-based registry

Genetic Disorders Requiring Risk-Reducing Surgical Management in Our Gynecological Oncology Practice